

CepTor CORP  
Form 8-K  
January 17, 2006  
**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): January 12, 2006

---

**CepTor Corporation**

(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

333-105793  
(Commission  
File Number)

11-2897392  
(IRS Employer  
Identification No.)

200 International Circle, Suite 5100, Hunt Valley, Maryland  
(Address of Principal Executive Offices)

21030  
(Zip Code)

Registrant's telephone number, including area code (410) 527-9998

N/A  
(Former Name or Former Address, if Changed Since Last Report)

## Edgar Filing: CepTor CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On January 17, 2006, CepTor Corporation (the Company ) issued a press release announcing that on January 12, 2006 it submitted an Investigational New Drug Application to the United States Food and Drug Administration to gain permission to begin human trials in Duchenne Muscular Dystrophy patients with Myodur, the Company's muscle cell-targeted calpain inhibitor compound.

For additional information, reference is made to the press release attached hereto as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated January 17, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEPTOR CORPORATION

Date: January 17, 2006

By: /s/ Donald W. Fallon  
Donald W. Fallon, SVP, Finance and Administration, Secretary  
and Chief Financial Officer